To address this need, HMP Global today announced the launch of the Radiopharmaceutical Education Institute (RPEI), a new clinician-focused educational platform from Oncology Learning Network (OLN), ...

Increasing use of blood tests to detect prostate cancer is leading to overworked doctors. NTNU has now created an AI diagnostic tool that can help ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...

Recent health updates highlight the FDA's approval of Lantheus' new prostate cancer imaging agent to enhance production ...

The FDA approved a new Lantheus prostate cancer imaging agent. South Carolina's measles cases rise. Medtronic's MiniMed shares drop in Nasdaq debut. A French probe exonerates Nestle in a baby death ...

The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...

Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...

New AI tool from UC San Diego and collaborators precisely maps the urethra on MRI to make prostate cancer radiation safer and reduce urinary side effects. Running on SDSC’s Expanse supercomputer, the ...

When the scientists analyzed the tissue samples, they found microplastic particles in nine out of ten tumor samples. Even more surprising, the amount of plastic in cancerous tissue was much higher ...

Thirty-eight years ago, I was initiated into the oldest and one of the largest Black fraternities in the world: Alpha Phi Alpha Fraternity, Inc. It was one of the happiest days of my life. In ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...